TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 (GLOBE...
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) --...
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing...
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of...
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin...
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI),...
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare SystemBERKELEY, Calif. and MAINZ, Germany, Feb. 21,...
Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10PITTSBURGH, Feb. 20, 2024 (GLOBE...
Significant efforts lie ahead, as the Black Book survey reveals that only 37% of medical practice respondents are receiving value-based...
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose...
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical...
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole...
STUDIO CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to announce the launch...
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review...
- Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar...
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional...
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and...
PALO ALTO, CA / ACCESSWIRE / February 7, 2024 / Bioz, Inc., a leading AI software company based in Silicon...
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
resTOR to be the first longevity clinic nationwide to offer the Company's blood-based epigenetic-genetic cardiovascular disease testsCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings,...